These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 22611046)

  • 1. Thrombo-embolism and antithrombotic therapy for heart failure in sinus rhythm. A joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis.
    Lip GY; Ponikowski P; Andreotti F; Anker SD; Filippatos G; Homma S; Morais J; Pullicino P; Rasmussen LH; Marin F; Lane DA;
    Eur J Heart Fail; 2012 Jul; 14(7):681-95. PubMed ID: 22611046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm: an executive summary of a joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis.
    Lip GY; Piotrponikowski P; Andreotti F; Anker SD; Filippatos G; Homma S; Morais J; Pullicino P; Rasmussen LH; Marín F; Lane DA;
    Thromb Haemost; 2012 Dec; 108(6):1009-22. PubMed ID: 23093044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis.
    Lip GY; Andreotti F; Fauchier L; Huber K; Hylek E; Knight E; Lane DA; Levi M; Marin F; Palareti G; Kirchhof P; ; Collet JP; Rubboli A; Poli D; Camm J
    Europace; 2011 May; 13(5):723-46. PubMed ID: 21515596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE).
    Lip GYH; Collet JP; Caterina R; Fauchier L; Lane DA; Larsen TB; Marin F; Morais J; Narasimhan C; Olshansky B; Pierard L; Potpara T; Sarrafzadegan N; Sliwa K; Varela G; Vilahur G; Weiss T; Boriani G; Rocca B;
    Europace; 2017 Nov; 19(11):1757-1758. PubMed ID: 29096024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antithrombotics in heart failure with reduced ejection fraction and normal sinus rhythm: an evidence appraisal.
    Prom R; Usedom JE; Dull RB
    Ann Pharmacother; 2014 Feb; 48(2):226-37. PubMed ID: 24259641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antithrombotic prophylaxis in patients with ventricular dysfunction: critical review of the literature and new perspectives].
    Scardi S; Mazzone C
    Ital Heart J Suppl; 2003 Mar; 4(3):201-9. PubMed ID: 12784754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of emerging antithrombotic therapy in the prevention of cardioembolic complications in patients with atrial fibrillation.
    Deedwania PC; Huang GW
    Am J Cardiovasc Drugs; 2011 Aug; 11(4):265-75. PubMed ID: 21740079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter.
    Cairns JA; Connolly S; McMurtry S; Stephenson M; Talajic M;
    Can J Cardiol; 2011; 27(1):74-90. PubMed ID: 21329865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Atrial fibrillation and thromboembolic events prevention. State of the art].
    Matteoli S; Trappolini M; Chillotti FM
    Minerva Cardioangiol; 2001 Feb; 49(1):1-13. PubMed ID: 11279381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antithrombotic therapy for heart failure in sinus rhythm.
    Subramaniam V; Davis RC; Shantsila E; Lip GY
    Fundam Clin Pharmacol; 2009 Dec; 23(6):705-17. PubMed ID: 19735305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is early antithrombotic therapy necessary in patients with bioprosthetic aortic valves in normal sinus rhythm?
    ElBardissi AW; DiBardino DJ; Chen FY; Yamashita MH; Cohn LH
    J Thorac Cardiovasc Surg; 2010 May; 139(5):1137-45. PubMed ID: 20303508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary--a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI).
    Lip GY; Huber K; Andreotti F; Arnesen H; Airaksinen JK; Cuisset T; Kirchhof P; Marín F;
    Eur Heart J; 2010 Jun; 31(11):1311-8. PubMed ID: 20447945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between degree of left ventricular dysfunction, symptom status, and risk of embolic events in patients with atrial fibrillation and heart failure.
    Sandhu RK; Hohnloser SH; Pfeffer MA; Yuan F; Hart RG; Yusuf S; Connolly SJ; McAlister FA; Healey JS
    Stroke; 2015 Mar; 46(3):667-72. PubMed ID: 25628308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of antithrombotic drugs in older people.
    Tufano A; Cerbone AM; Di Minno G
    Minerva Med; 2002 Feb; 93(1):13-26. PubMed ID: 11850611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA.
    Wieloch M; Själander A; Frykman V; Rosenqvist M; Eriksson N; Svensson PJ
    Eur Heart J; 2011 Sep; 32(18):2282-9. PubMed ID: 21616951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral anticoagulation therapy in heart failure patients in sinus rhythm: a systematic review and meta-analysis.
    Rengo G; Pagano G; Squizzato A; Moja L; Femminella GD; de Lucia C; Komici K; Parisi V; Savarese G; Ferrara N; Perrone-Filardi P; Leosco D
    PLoS One; 2013; 8(1):e52952. PubMed ID: 23301006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implications of the CHA(2)DS(2)-VASc and HAS-BLED Scores for thromboprophylaxis in atrial fibrillation.
    Lip GY
    Am J Med; 2011 Feb; 124(2):111-4. PubMed ID: 20887966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.
    Flaker GC; Gruber M; Connolly SJ; Goldman S; Chaparro S; Vahanian A; Halinen MO; Horrow J; Halperin JL;
    Am Heart J; 2006 Nov; 152(5):967-73. PubMed ID: 17070169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticoagulation for heart failure: selecting the best therapy.
    Kohsaka S; Homma S
    Expert Rev Cardiovasc Ther; 2009 Oct; 7(10):1209-17. PubMed ID: 19814664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiplatelet and anticoagulant agents in heart failure: current status and future perspectives.
    Gurbel PA; Tantry US
    JACC Heart Fail; 2014 Feb; 2(1):1-14. PubMed ID: 24622113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.